Principal Financial Group Inc. Purchases New Stake in Keros Therapeutics, Inc. $KROS

Principal Financial Group Inc. purchased a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 59,594 shares of the company’s stock, valued at approximately $658,000.

A number of other large investors have also added to or reduced their stakes in KROS. Financial Management Professionals Inc. purchased a new position in shares of Keros Therapeutics in the fourth quarter valued at about $29,000. Caitong International Asset Management Co. Ltd raised its stake in shares of Keros Therapeutics by 254.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after acquiring an additional 1,166 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Keros Therapeutics by 149.2% during the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after purchasing an additional 1,888 shares during the period. New York State Common Retirement Fund boosted its holdings in shares of Keros Therapeutics by 264.1% during the second quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock worth $142,000 after purchasing an additional 7,700 shares during the period. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Keros Therapeutics by 8.6% in the second quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock worth $166,000 after purchasing an additional 988 shares during the last quarter. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Price Performance

Shares of NASDAQ KROS opened at $10.07 on Friday. Keros Therapeutics, Inc. has a 1 year low of $9.69 and a 1 year high of $22.55. The stock has a market capitalization of $199.29 million, a P/E ratio of -3.35 and a beta of 0.97. The company’s 50-day moving average is $10.70 and its 200 day moving average is $12.70.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($1.21) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.19). The company had revenue of $0.37 million during the quarter, compared to analysts’ expectations of $1.93 million. Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%. Research analysts anticipate that Keros Therapeutics, Inc. will post -5.19 earnings per share for the current year.

Analysts Set New Price Targets

KROS has been the topic of a number of research analyst reports. Weiss Ratings downgraded Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 15th. Wall Street Zen cut Keros Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Finally, Zacks Research lowered Keros Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $20.40.

Insiders Place Their Bets

In related news, Director Alpna Seth sold 2,625 shares of Keros Therapeutics stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $10.72, for a total transaction of $28,140.00. Following the sale, the director directly owned 9,767 shares in the company, valued at $104,702.24. The trade was a 21.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Julius Knowles sold 2,625 shares of Keros Therapeutics stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total value of $28,166.25. Following the sale, the director owned 10,958 shares in the company, valued at $117,579.34. This represents a 19.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 8,425 shares of company stock worth $89,994. Company insiders own 12.60% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.